Connor Clark & Lunn Investment Management Ltd. purchased a new position in Humana Inc. (NYSE:HUM - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 48,531 shares of the insurance provider's stock, valued at approximately $19,277,000.
Several other institutional investors have also bought and sold shares of HUM. Johnson Financial Group Inc. purchased a new stake in Humana in the second quarter worth $26,000. Trust Co. of Vermont purchased a new position in shares of Humana during the 2nd quarter valued at $28,000. Bogart Wealth LLC lifted its position in shares of Humana by 192.0% during the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider's stock valued at $29,000 after buying an additional 48 shares during the last quarter. MidFirst Bank bought a new position in shares of Humana during the 2nd quarter worth $35,000. Finally, Montag A & Associates Inc. grew its stake in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after acquiring an additional 94 shares during the period. Hedge funds and other institutional investors own 92.38% of the company's stock.
Humana Price Performance
Shares of NYSE HUM opened at $388.92 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The stock has a market cap of $46.70 billion, a PE ratio of 36.79, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72. The stock has a fifty day moving average of $383.88 and a 200-day moving average of $285.00.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The business had revenue of $40.89 billion for the quarter, compared to analysts' expectations of $40.58 billion. During the same quarter in the prior year, the firm posted $6.27 EPS. The firm's quarterly revenue was up 26.2% on a year-over-year basis. Equities research analysts anticipate that Humana Inc. will post 9.12 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the company. William Blair started coverage on Humana in a research note on Wednesday, May 20th. They issued an "outperform" rating on the stock. Zacks Research lowered shares of Humana from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 11th. Wells Fargo & Company upgraded shares of Humana from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $227.00 to $502.00 in a research note on Monday, July 13th. Cantor Fitzgerald boosted their price target on shares of Humana from $264.00 to $300.00 and gave the company a "neutral" rating in a research report on Tuesday, July 7th. Finally, Jefferies Financial Group raised shares of Humana from a "buy" rating to a "buy" rating in a research report on Wednesday, May 20th. Fourteen analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Humana currently has an average rating of "Hold" and an average target price of $403.91.
Check Out Our Latest Stock Analysis on HUM
Humana Company Profile
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
